October 12th, 2021 photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Tokyo, Japan; Representative Director, President and CEO: Yoshitaka Kitao) and a leader in the pharmaceutical development, translation and global commercialization of 5aminolevulinic acid (“5-ALA”) (*1) today announces that results of an investigatorinitiated proof-of-concept study conducted by St. Olavs Hospital, Trondheim University Hospital (Trondheim, Norway) with a drug support from photonamic to evaluate treatment safety and tolerability of Extracorporeal Photopheresis (ECP) (*2) with 5-ALA in patients with chronic graft-versus-host disease (cGvHD) were published in “Pharmaceutics” on September 26th 2021. ....more